Sanofi India Limited (SIL) today released its financial results for the quarter ending June 30, 2025. The company reported a 9% decline in net sales for its continuing operations on a comparable basis. In the domestic market, the newly launched diabetes therapy Soliqua® continued to gain market traction, strengthening the company’s diabetes care portfolio. Toujeo®, another key product in the insulin segment, maintained its upward trend with high single-digit growth.
SIL’s strategic partnerships in the Cardiovascular (CV) and Central Nervous System (CNS) therapeutic areas have progressed as planned, expanding market access and laying a strong foundation for further business growth. Export sales declined during the quarter due to the absence of one-off sales from Consumer Healthcare (CHC) products in 2024 and the previously announced phase-out of the Zentiva product range.
For the year-to-date period ending June 2025, the company reported a 2% decline in net sales and a 6% increase in profit from operations compared to the same period last year. The improvement in operating profit reflects cost discipline and continued efforts to improve operational performance.
Rachid Ayari, Whole Time Director and Chief Financial Officer, commented, “This has been a pivotal year in our transformation journey. Our insulin range has shown strong growth, with Toujeo® continuing its positive trajectory and Soliqua® making a successful entry into the market. We are also seeing encouraging progress in our CV and CNS segments through strategic collaborations. Our focus remains on expanding access, maintaining operational excellence, and delivering innovative solutions to support healthcare delivery in India.”
Sanofi has had a longstanding presence in India for nearly 70 years, building trust through its commitment to improving health outcomes. The company operates across the healthcare continuum—from prevention and wellness to treatment and patient support. Its India Charitable Access Program (InCAP) is the country’s longest-running initiative providing free treatment to individuals with Lysosomal Storage Disorders.
Sanofi India also conducts clinical trials locally, ensuring earlier access to global innovations. Its manufacturing site in Goa serves both domestic and international markets, supplying products to over 60 countries. In Hyderabad, Sanofi has established one of its four global talent hubs, offering a wide range of services to global operations. Recognized by the Top Employers Institute since 2019 for excellence in people practices, Sanofi operates in India through Sanofi India Limited (SIL) and Sanofi Healthcare India Pvt Ltd (SHIPL).
